Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis Bioequivalence Study in Healthy Adults
NCT07470866Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time curve and Maximum observed plasma concentration. Started Mar 2026; status: terminated.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT07470866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470866.